NASDAQ$ROIV
Roivant Sciences Ltd · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Roivant Sciences reported financial results for the quarter ended September 30, 2021 and provided a business update.
Roivant Sciences reported its financial results for the second fiscal quarter ended September 30, 2021. The company's cash and cash equivalents increased to $2.5 billion. Roivant closed its business combination with Montes Archimedes Acquisition Corp. and began trading on Nasdaq under the ticker "ROIV."
- Roivant began trading on Nasdaq under “ROIV”; cash balance increased to $2.5 billion.
- Dermavant announced final results from the Phase 3 PSOARING 3 long-term extension study of tapinarof in patients with plaque psoriasis (n=763).
- Aruvant released clinical data from third and fourth patients dosed in ongoing Phase 1/2 trial of ARU-1801 in sickle cell disease, showing zero vaso-occlusive events 18 and 12 months after dosing, respectively
- Roivant closed its business combination with Montes Archimedes Acquisition Corp. (“MAAC”) and concurrent PIPE financing, and Roivant began trading on Nasdaq under the ticker “ROIV.”
Headline financials
Revenue & EPS history
Roivant Sciences · Revenue · Quarterly
$12.5M
Forward guidance
Roivant anticipates several milestones across its portfolio of companies. Dermavant expects an FDA decision on tapinarof for plaque psoriasis in Q2 2022 and topline data from a Phase 3 trial for atopic dermatitis in H1 2023. Immunovant plans to initiate a pivotal trial for batoclimab in myasthenia gravis in early 2022 and re-initiate programs in thyroid eye disease and warm autoimmune hemolytic anemia.
Tailwinds
- Dermavant expects a decision from the FDA on the approval of tapinarof for the treatment of adults with plaque psoriasis in the second quarter of calendar year 2022.
- Dermavant expects to report topline data from Dermavant’s Phase 3 clinical trial of tapinarof for the treatment of atopic dermatitis in the first half of calendar year 2023.
- Immunovant plans to initiate a pivotal trial evaluating batoclimab for the treatment of myasthenia gravis in the early part of calendar year 2022.
- Immunovant plans to re-initiate its programs in thyroid eye disease and warm autoimmune hemolytic anemia.
- Aruvant is expected to report additional clinical data from its ongoing Phase 1/2 trial of ARU-1801 in sickle cell disease patients at ASH.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2022
+3.3%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.4%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+22.1%
Q3 2026
Best reaction
-5.5%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +14.9% | — | — | |
| Q3 2026 | +22.1% | +26.8% | +36.1% | |
| Q2 2026 | +2.6% | -1.6% | -1.8% | |
| Q1 2026 | -2.8% | +3.1% | +19.8% | |
| Q4 2025 | +6.4% | +5.9% | +7.3% | |
| Q4 2024 | -3.4% | +0.0% | -1.5% | |
| Q3 2024 | +4.1% | +6.6% | -5.9% | |
| Q2 2024 | +5.6% | +1.8% | +22.7% | |
| Q1 2024 | -5.2% | -6.1% | -3.5% | |
| Q4 2023 | +9.4% | +7.8% | +28.8% | |
| Q3 2023 | +9.7% | +8.2% | +7.8% | |
| Q2 2023 | +7.4% | -3.1% | +39.9% | |
| Q1 2023 | -5.5% | -15.3% | -15.8% | |
| Q4 2022 | -4.1% | -5.6% | -11.8% | |
| Q3 2021 | +5.1% | -3.2% | -25.4% | |
| Q3 2022 | +5.4% | -3.2% | -25.4% | |
| Q2 2022 | -2.4% | -4.8% | +6.8% | |
| Q2 2021 | -3.8% | -4.8% | +6.8% | |
| Q1 2021 | +0.1% | +0.7% | -38.7% | |
| Q1 2022 | +0.0% | +0.7% | -38.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro